Multiple-dose parallel-group pharmacodynamics, safety, tolerability and pharmacokinetics of oral AGG-523 in mild to moderate osteoarthritis
Osteoarthritis
Enrolment not recorded · Results not recorded
Loading the evidence…
Drug · No confident ChEMBL entity located for the Wyeth/Pfizer development code AGG-523, an ADAMTS-4/ADAMTS-5 (aggrecanase) inhibitor, so resolved=false. Clinical development is nonetheless documented: four completed phase 1 CTgov studies in osteoarthritis and healthy volunteers.
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Osteoarthritis
Enrolment not recorded · Results not recorded
Osteoarthritis
Enrolment: 2 · Results not recorded
Healthy Subjects · Osteoarthritis
Enrolment not recorded · Results not recorded
Healthy
Enrolment not recorded · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Meniscal tear-induced joint instability (traumatic knee injury)
Oral AGG-523 significantly attenuated the injury-induced release of aggrecanase-generated aggrecan fragments into rat joint fluid.
Extraction: extract · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.